Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Human Long-R3-IGF-I produced in E. coli is a single, non-glycosylated, polypeptide chain containing 83 amino acids and having a molecular mass of 9.111 kDa.
The ED50, calculated by the dose-dependant proliferation of murine BALB\C 3T3 cells is less than 1.0 ng/ml, corresponding to a specific activity of 1.0 x 106 IU/mg. For most in-vitro applications, Long-R3-IGF-I exerts its biological activity in the concentration range of 0.2-20 ng/ml.
Less than 0.1ng/ug (1IEU/ug) of Long-R3-IGF-I.
>95% by SDS-PAGE and RP-HPLC.
Lyophilized Long-R3-IGF-I although stable at room temperature for 3 weeks, should be stored desiccated below -18oC. Upon reconstitution Long-R3-IGF-I should be stored at 4oC between 2-7 days and for future use below -18oC. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Aliquot to avoid repeated freeze-thaw cycles.
It is recommended to reconstitute the lyophilized Long-R3-IGF-I in 500mM acetic acid not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
PDB rendering based on 1bqt.
Human Long Arg3 Insulin-like Growth Factor-I (Long-R3-IGF-I) is an 83 amino acid analog of human IGF-I comprising the complete human IGF-I sequence with the substitution of an Arg for the Glu at position 3 (hence R3), and a 13 amino acid extension peptide at the N-terminus. Scientists have engineered this analog with the express purpose of increasing biological activity. Human Long-R3-IGF-I is significantly more potent than human IGF-I in vitro. The enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.